Vnitřní lékařství 6/2020

PŘEHLEDOVÉ ČLÁNKY Perkutánní okluze ouška levé síně | E9  / Vnitř Lék 2020; 66(6): e3–e9 /  VNITŘNÍ LÉKAŘSTVÍ www.casopisvnitrnilekarstvi.cz LITERATURA 1. Lloyd-Jones DM, Wang TJ, Leip EP, et al. Lifetime Risk for Development of Atrial Fibrilla- tion. Circulation 2004; 110: 1042–1046. 2. Staerk L, Wang B, Preis SR, et al. Lifetime risk of atrial fibrillation according to optimal, borderline, or elevated levels of risk factors: cohort study based on longitudinal data from the Framingham Heart Study. BMJ 2018; k1453. https://doi.org/10.1136/bmj.k1453 3. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stro- ke: the Framingham Study. Stroke 1991; 22: 983–988. 4. Libby P, Braunwald E. Braunwald’s heart disease: A textbook of cardiovascular medici- ne (8th ed.). Philadelphia, Pa 2008, Edinburgh: Saunders Elsevier 5. Blackshear JL, Odell JA. Appendage obliteration to reduce stroke in cardiac surgical pa- tients with atrial fibrillation. The Annals of Thoracic Surgery 1996; 61: 755–759. 6. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial Fibrillation. Annals of Internal Medi- cine 2007; 146: 857. 7. Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. European Heart Journal 2016; 37: 2893–2962. 8. Rubboli A. Incidence, clinical impact and risk of bleeding during oral anticoagulation therapy. World Journal of Cardiology 2011; 3: 351. 9. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation. New England Journal of Medicine 2011; 365: 883–891. 10. Hicks T, Stewart F, Eisinga A. NOACs versus warfarin for stroke prevention in patients with AF: a systematic review and meta-analysis. Open Heart 2016; 3: e000279. 11. Kimmel SE. The Influence of Patient Adherence on Anticoagulation Control With War- farin. Archives of Internal Medicine 2007; 167: 229. 12. Pfeilschifter LS, Hohmann C, Niemann D, et al. Adherence to oral anticoagulant thera- py in secondary stroke prevention dash; impact of the novel oral anticoagulants. Patient Preference and Adherence 2015; 1695. https://doi.org/10.2147/ppa.s88994 13. Katz ES, Tsiamtsiouris T, Applebaum RM, et al. Surgical left atrial appendage ligation is frequently incomplete: a transesophageal echocardiographic study. Journal of the Ame- rican College of Cardiology 2000; 36: 468–471. 14. Friedman DJ, Piccini JP, Wang T, et al. Association Between Left Atrial Appendage Oc- clusion and Readmission for Thromboembolism Among Patients With Atrial Fibrillation Undergoing Concomitant Cardiac Surgery. JAMA 2018; 319: 365. 15. Regazzoli D, Ancona F, Trevisi N, et al. Left Atrial Appendage: Physiology, Pathology, and Role as a Therapeutic Target. BioMed Research International 2015; 2015: 1–13. 16. Sadler TW, Langman J. Langman’s medical embryology (12th ed.). Philadelphia: Wol- ters Kluwer Health/Lippincott Williams & Wilkins 2012. 17. Ho SY, Cabrera JA, Sanchez-Quintana D. Left Atrial Anatomy Revisited. Circulation: Arr- hythmia and Electrophysiology 2012; 5: 220–228. 18. Beigel R, Wunderlich NC, Ho SY, et al. The Left Atrial Appendage: Anatomy, Function, and Noninvasive Evaluation. JACC: Cardiovascular Imaging 2014; 7: 1251–1265. 19. Di Biase L, Santangeli P, Anselmino M, et al. Does the Left Atrial Appendage Morpholo- gy Correlate With the Risk of Stroke in Patients With Atrial Fibrillation? Journal of the Ame- rican College of Cardiology 2012; 60: 531–538. 20. Hoit BD, Shao Y, Tsai LM, et al. Altered left atrial compliance after atrial appendectomy. Influence on left atrial and ventricular filling. Circ Res 1993; 72: 167–175. 21. Bansal M, Kasliwal RR. Echocardiography for left atrial appendage structure and fun- ction. Indian Heart Journal 2012; 64: 469–475. 22. García-fernández MA, Torrecilla EG, San román D et al. Left atrial appendage Do- ppler flow patterns: implications on thrombus formation. Am Heart J 1992; 124: 955–961. 23. Transesophageal echocardiographic correlates of thromboembolism in high-risk pa- tients with nonvalvular atrial fibrillation. The Stroke Prevention in Atrial Fibrillation Investi- gators Committee on Echocardiography. Ann Intern Med 1998; 128: 639–647. 24. Chapeau C, Gutkowska J, Schiller PW, et al. Localization of immunoreactive synthe- tic atrial natriuretic factor (ANF) in the heart of various animal species. J Histochem Cy- tochem 1985; 33: 541–550. 25. Calkins H, Hindricks G, Cappato R, et al. 2017 HRS/EHRA/ECAS/APHRS/SOLAECE ex- pert consensus statement on catheter and surgical ablation of atrial fibrillation. Heart Rhythm 2017; 14: e275–e444. 26. Friedman DJ, Black-Maier EW, Barnett AS, et al. Left Atrial Appendage Electrical Isolation for Treatment of Recurrent Atrial Fibrillation. JACC: Clinical Electrophysiology 2018; 4: 112–120. 27. Rillig A, Tilz RR, Lin T, et al. Unexpectedly High Incidence of Stroke and Left Atrial Ap- pendage Thrombus Formation After Electrical Isolation of the Left Atrial Appendage for the Treatment of Atrial Tachyarrhythmias. Circulation: Arrhythmia and Electrophysiology 2016; 9: https://doi.org/10.1161/circep.115.003461 28. January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation. Circula- tion 2019; https://doi.org/10.1161/cir.0000000000000665 29. Kernan WN, Ovbiagele B, Black HR, et al. Guidelines for the Prevention of Stroke in Pa- tients With Stroke and Transient Ischemic Attack. Stroke 2014; 45: 2160–2236. 30. Alkhouli M, Rihal CS, Holmes jr. DR. Transseptal Techniques for Emerging Structural He- art Interventions. JACC: Cardiovascular Interventions 2016; 9: 2465–2480. 31. Perrotta L, Bordignon S, Dugo D, et al. Complications From Left Atrial Appendage Ex- clusion Devices. Journal of atrial fibrillation 2014; 7: 1034. 32. Holmes DR, Reddy VY, Turi ZG, et al. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a ran- domised non-inferiority trial. The Lancet 2009; 374: 534–542. 33. Holmes jr. DR, Kar S, Price MJ, et al. Prospective Randomized Evaluation of the Wat- chman Left Atrial Appendage Closure Device in Patients With Atrial Fibrillation Versus Lon- g-Term Warfarin Therapy. Journal of the American College of Cardiology 2014; 64: 1–12. 34. Reddy VY, Möbius-Winkler S, Miller MA, et al. Left Atrial Appendage Closure With the Watchman Device in Patients With a Contraindication for Oral Anticoagulation. Journal of the American College of Cardiology 2013; 61: 2551–2556. 35. Reddy VY, Doshi SK, Kar S, et al. 5-Year Outcomes After Left Atrial Appendage Closure. Journal of the American College of Cardiology 2017; 70: 2964–2975. 36. Boersma LVA, Schmidt B, Betts TR, et al. Implant success and safety of left atrial appen- dage closure with the WATCHMAN device: peri-procedural outcomes from the EWOLU- TION registry. European Heart Journal 2016; 37: 2465–2474. 37. Tzikas A, Shakir S, Gafoor S, et al. Left atrial appendage occlusion for stroke preventi- on in atrial fibrillation: multicentre experience with the AMPLATZER Cardiac Plug. EuroIn- tervention 2016; 11: 1170–1179. 38. Tzikas A. Left Atrial Appendage Occlusion with Amplatzer Cardiac Plug and Am- platzer Amulet: a Clinical Trials Update. Journal of Atrial Fibrillation 2017; 10: https://doi. org/10.4022/jafib.1651 39. Korsholm K, Nielsen K, Jensen J, et al. Transcatheter left atrial appendage occlusion in patients with atrial fibrillation and a high bleeding risk using aspirin alone for post-im- plant antithrombotic therapy. EuroIntervention 2017; 12: 2075–2082. 40. WeiseFK,BordignonS,PerrottaL,etal.Short-termdualantiplatelettherapyafter interventi- onal leftatrialappendageclosurewithdifferentdevices.EuroIntervention2018;13:2138–2146. 41. Srivastava MC, See VY, Dawood MY, et al. A review of the LARIAT device: insights from the cumulative clinical experience. SpringerPlus 2015; 4: https://doi.org/10.1186/s40064- 015-1289-8 42. Han FT, Bartus K, Lakkireddy D, et al. The effects of LAA ligation on LAA electrical ac- tivity. Heart Rhythm 2014; 11: 864–870. 43. Afzal MR, Kanmanthareddy A, Earnest M, et al. Impact of left atrial appendage exclu- sion using an epicardial ligation system (LARIAT) on atrial fibrillation burden in patients with cardiac implantable electronic devices. Heart Rhythm 2015; 12: 52–59.